Platelet microparticles in relation to disease-related risk factors in polycythemia vera and essential thrombocythemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00074874" target="_blank" >RIV/65269705:_____/21:00074874 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/archiv-cisel/2021-supplementum-2" target="_blank" >https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/archiv-cisel/2021-supplementum-2</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Platelet microparticles in relation to disease-related risk factors in polycythemia vera and essential thrombocythemia

Popis výsledku v původním jazyce

Introduction: Thromboembolism is a common life-threatening complication in patients with polycythemia vera (PV) and essential thrombocythemia (ET), accounting for a mortality rate of 41% and 26% of patients with an incidence rate of 3.8% and 1.9% per year, respectively. Besides older age and history of thrombosis being the definite risk factors of thrombosis, disease-related factors, such as JAK2V617F mutation and blood count results, have been linked to the increased risk of thrombosis. Circulating microparticles (MPs) may contribute to thrombosis through expressing pro-coagulant phosphatidylserine and tissue factor. Methods: The absolute count of platelet microparticles (PMPs) and MPs procoagulant activity (MP-activity) were evaluated in relation to disease-related thrombotic risk factors in a cohort of 170 patients (51 with PV and 119 with ET). MP-activity was measured by the Zymuphen functional assay in 363 samples. PMPs were enumerated by flow cytometry in 466 samples. Results: Compared to healthy individuals, patients with ET or PV have significantly higher MPs levels. The pathological values of MP-activity are significantly higher in PV patients than in ET patients. Regarding disease-related risk factors, the presence of JAK2V617F mutation is associated with a significantly higher PMPs count. During the follow-up, patients who had their hematocrit value &gt; 45%, platelet count &gt; 400x109/L, or leukocytes count &gt; 10x109/L have significantly increased MPs levels. Patients with a history of thrombosis before PV or ET dia gnosis have signifi cantly higher MP-activity values than thrombosis-free patients. Treatment during the follow-up probably affects MPs levels as patients with arterial or venous thrombotic complications after dia gnosis have significantly lower MPs values. Conclusion: Levels of platelet microparticles and their procoagulant activity are increased in disease-related risk factors for thrombosis, and this relationship indicates a possible role of MPs in thrombotic complications of patients with polycythemia vera and essential thrombocythemia.

Název v anglickém jazyce

Platelet microparticles in relation to disease-related risk factors in polycythemia vera and essential thrombocythemia

Popis výsledku anglicky

Introduction: Thromboembolism is a common life-threatening complication in patients with polycythemia vera (PV) and essential thrombocythemia (ET), accounting for a mortality rate of 41% and 26% of patients with an incidence rate of 3.8% and 1.9% per year, respectively. Besides older age and history of thrombosis being the definite risk factors of thrombosis, disease-related factors, such as JAK2V617F mutation and blood count results, have been linked to the increased risk of thrombosis. Circulating microparticles (MPs) may contribute to thrombosis through expressing pro-coagulant phosphatidylserine and tissue factor. Methods: The absolute count of platelet microparticles (PMPs) and MPs procoagulant activity (MP-activity) were evaluated in relation to disease-related thrombotic risk factors in a cohort of 170 patients (51 with PV and 119 with ET). MP-activity was measured by the Zymuphen functional assay in 363 samples. PMPs were enumerated by flow cytometry in 466 samples. Results: Compared to healthy individuals, patients with ET or PV have significantly higher MPs levels. The pathological values of MP-activity are significantly higher in PV patients than in ET patients. Regarding disease-related risk factors, the presence of JAK2V617F mutation is associated with a significantly higher PMPs count. During the follow-up, patients who had their hematocrit value &gt; 45%, platelet count &gt; 400x109/L, or leukocytes count &gt; 10x109/L have significantly increased MPs levels. Patients with a history of thrombosis before PV or ET dia gnosis have signifi cantly higher MP-activity values than thrombosis-free patients. Treatment during the follow-up probably affects MPs levels as patients with arterial or venous thrombotic complications after dia gnosis have significantly lower MPs values. Conclusion: Levels of platelet microparticles and their procoagulant activity are increased in disease-related risk factors for thrombosis, and this relationship indicates a possible role of MPs in thrombotic complications of patients with polycythemia vera and essential thrombocythemia.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů